Cellino aims to significantly expand patient access to cell therapies with autonomous end-to-end manufacturing
Leaps by Bayer leads $80M Series A Financing for Cellino Biotech to Autonomize Stem Cell Therapy Manufacturing
28-Jan-2022 -
Cellino Biotech, Inc., an autonomous cell therapy manufacturing company, announced the completion of a Series A financing of $80 million, led by the impact investment arm of Bayer AG – Leaps by Bayer – 8VC, and Humboldt Fund. New investors in the round include Felicis Ventures and others, joining ...
artificial intelligence
automation
cell therapies
+4